Investigators assessed long-term PFS and safety results for acalabrutinib, bendamustine, and rituximab in the phase 3 ECHO trial.

Investigators evaluated the proportion, clinical characteristics, and survival of patients with lung cancer who met or were excluded from USPSTF criteria and used institutional and published data to ...

The EPCORE FL-1 trial evaluated epcoritamb plus lenalidomide and rituximab versus plus lenalidomide and rituximab for ...

At ASH 2025, researchers reported on 3-year efficacy and safety of lisocabtagene maraleucel in follicular lymphoma patients being treated in the third-line setting or later.

In the phase 2 Smart Stop trial, researchers investigated the feasibility of achieving durable complete responses in DLBCL without the use of chemotherapy.

In this phase 2 study, researchers sought to determine whether cytoreductive treatment with rituximab followed by epcoritamab would deepen responses and lower risk of cytokine release syndrome.

Experts explore the multifaceted barriers to cryopreserved sperm use and propose specific solutions to help survivors achieve their reproductive goals.

Investigators reported 1-year disease-free survival results from patients with BCG-unresponsive papillary disease-only high-risk NMIBC in the phase 2b SunRISe-1 trial.

Guidelines recommend older adults with newly diagnosed AML should be offered antileukemic therapy over best supportive care.

Study researchers aimed to describe the cumulative incidence of financial toxicity among families with a child being treated for ALL, as well as the sociodemographic factors associated with the ...

Investigators sought compare the efficacy and safety of a chemo-free approach to TKI + chemotherapy in newly-diagnosed adult Ph+ ALL.

Researchers sought to determine whether zanubrutinib plus obinutuzumab would be effective in treating patients with R/R FL.